All In Biotech

Drug Trial Radar · NCT04113616

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Mar 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

70

Actual

Start

Sep 25, 2019

Primary completion

Sep 27, 2023

Study completion Sep 27, 2023

Sponsor

Lead sponsor
Kartos Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, when administered alone and in combination with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid Leukemia (AML) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be relapsed/refractory (having failed prior therapy) and will be assigned to receive monotherapy (KRT-232 alone) or combination therapy (KRT-232 with LDAC or KRT-232 with Decitabine).

Conditions

  • Relapsed or Refractory Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

Interventions

  • KRT-232Drug

    KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.

  • CytarabineDrug

    Cytarabine is an anti-cancer chemotherapy drug taken via injection.

  • DecitabineDrug

    Decitabine is an anti-cancer chemotherapy drug taken via injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: To determine KRT-232 recommended phase 2 dose (RP2D)Time frame: 28 Days
  2. Part B: To determine the RP2D of KRT-232Time frame: 2 years after last patient enrolled

Locations

59 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Chicago

    Chicago, Illinois

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Mount Sinai

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Weill Cornell

    New York, New York

  • The Ohio State University

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • MD Anderson Cancer Center

    Houston, Texas

  • Monash Health

    Clayton, Australia

  • St. George Hospital

    Kogarah, Australia

  • Royal Perth Hospital

    Perth, Australia

  • Calvary Mater Newcastle Hospital

    Waratah, Australia

  • Perth Blood Institute

    West Perth, Australia

  • Institut Jules Bordet

    Anderlecht, Belgium

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • Centre Hospitalier (CH) Jolimont

    Haine-Saint-Paul, Belgium

  • AZ Turnhout

    Turnhout, Belgium

  • Centre Hospitalier Universitaire (CHU) de Bordeaux

    Bordeaux, France

  • Institut Paoli Calmettes

    Marseille, France

  • Centre Hospitalier Universitaire (CHU) de Nice

    Nice, France

  • Hôpital Saint-Louis

    Paris, France

  • Universitätsklinikum Halle

    Halle, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • University Hospital Jena

    Jena, Germany

  • Universitätsklinikum Leipzig

    Leipzig, Germany

  • Universitaetsklinikum Schleswig-Holstein

    Lübeck, Germany

  • Semmelweis Egyetem

    Budapest, Hungary

  • Del-Pesti Centrumkorhaz Orszagos Hematologiai es Infektologi

    Budapest, Hungary

  • szabolcs-szatmár-bereg megyei kórházak és egyetemi oktatókórház Jósa András Oktatókórház

    Debrecen, Hungary

  • Somogy Megyei KAposi Mor Oktato Korhaz

    Kaposvár, Hungary

  • Rambam Health Care Campus

    Haifa, Israel

  • Hadassah Medical Center Ein Kerem

    Jerusalem, Israel

  • The Chaim Sheba Medical Center

    Ramat Gan, Israel

  • Tel-Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Assaf Harofeh Medical Center AHMC

    Tel Aviv, Israel

  • AOU Policlinico S.Orsola-Malpighi

    Bologna, Italy

  • AORMN Hospital Hematology and BMT Center

    Pesaro, Italy

  • AOUS Le Scotte

    Siena, Italy

  • Universitaria Maggiore della Carità Novara

    Novara, Piedmont, Italy

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.